Results from the latest Zytiga clinical trials show that patients on the placebo arm had a median overall survival (OS) of 27.2 months while the patients on the Zytiga treated arm had such a good survival time that the median value has not yet been reached.
It is interesting to compare the placebo arm OS time with that seen for Sipuleucel-T (Provenge) when it underwent clinical trials in the same class of patient population to establish its efficacy. The OS time for Provenge was found to be 25.9 months. The Zytiga placebo arm had an OS time of 27.2 months so this data taken together shows that under clinical trial conditions a placebo has a greater effect than Provenge.
No comments:
Post a Comment